EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biomimetic Nano‐Degrader Based CD47‐SIRPα Immune Checkpoint Inhibition Promotes Macrophage Efferocytosis for Cardiac Repair

Jinfeng Gao, Zhiqing Pang, Qiaozi Wang, Yiwen Tan, Qiyu Li, Haipeng Tan, Jing Chen, Wusiman Yakufu, Zhengmin Wang, Hongbo Yang, Jinyan Zhang, Dili Sun und 6 weitere

Advanced Science · 2024-06 · 11 (24)

DOI: 10.1002/advs.202306388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 13.03.2024. Verfasst von Jinfeng Gao und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, 20032, China. Hauptthemen laut MEDLINE: CD47 Antigen, Receptors, Immunologic, Macrophages. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Clinical Research Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD47‐SIRPα axis is an immunotherapeutic target in tumor therapy. However, current monoclonal antibody targeting CD47‐SIRPα axis is associated with on‐target off‐tumor and antigen sink effects, which significantly limit its potential clinical application. Herein, a biomimetic nano‐degrader is developed to inhibit CD47‐SIRPα axis in a site‐specific manner through SIRPα degradation, and its efficacy in acute myocardial infarction (AMI) is evaluated. The nano‐degrader is constructed by hybridizing liposome with red blood cell (RBC) membrane (RLP), which mimics the CD47 density of senescent RBCs and possesses a natural high‐affinity binding capability to SIRPα on macrophages without signaling capacity. RLP would bind with SIRPα and induce its lysosomal degradation through receptor‐mediated endocytosis. To enhance its tissue specificity, Ly6G antibody conjugation (aRLP) is applied, enabling its attachment to neutrophils and accumulation within inflammatory sites. In the myocardial infarction model, aRLP accumulated in the infarcted myocardium blocks CD47‐SIRPα axis and subsequently promoted the efferocytosis of apoptotic cardiomyocytes by macrophage, improved heart repair. This nano‐degrader efficiently degraded SIRPα in lysosomes, providing a new strategy for immunotherapy with great clinical transformation potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD47 AntigenReceptors, ImmunologicMacrophagesAnimalsMiceDisease Models, AnimalMyocardial InfarctionImmune Checkpoint InhibitorsAntigens, DifferentiationPhagocytosisBiomimeticsHumansEfferocytosis

Stichwörter der Autor:innen

CD47‐SIRPα axisacute myocardial infarctionefferocytosisreceptor‐mediated internalizationtargeted protein degradation

Substanzen

CD47 AntigenReceptors, ImmunologicImmune Checkpoint InhibitorsAntigens, DifferentiationSirpa protein, mouse

Autor:innen und Institutionen

  • Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, 20032, China.
  • National Clinical Research Center for Interventional Medicine, Shanghai Clinical Research Center for Interventional Medicine, 180 Feng Lin Road, Shanghai, 200032, China.
  • School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, 826 Zhangheng Road, Shanghai, 200030, China.
  • Institute of Biomedical Sciences, Fudan University, Shanghai, 20032, China.

ORCID-Profile: Zheyong Huang

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Shanghai Clinical Research Center
  • Shanghai Municipal Key Clinical Specialty

Zitieren

APA

Gao, J., Pang, Z., Wang, Q., Tan, Y., Li, Q., Tan, H., Chen, J., Yakufu, W., Wang, Z., Yang, H., Zhang, J., Sun, D., Weng, X., Wang, Q., Qian, J., Song, Y., Huang, Z., & Ge, J. (2024). Biomimetic Nano‐Degrader Based CD47‐SIRPα Immune Checkpoint Inhibition Promotes Macrophage Efferocytosis for Cardiac Repair. Advanced Science, 11(24). https://doi.org/10.1002/advs.202306388

Vancouver

Gao J, Pang Z, Wang Q, Tan Y, Li Q, Tan H, et al. Biomimetic Nano‐Degrader Based CD47‐SIRPα Immune Checkpoint Inhibition Promotes Macrophage Efferocytosis for Cardiac Repair. Advanced Science. 2024;11(24). doi:10.1002/advs.202306388

BibTeX
@article{Gao2024,
  author = {Gao, Jinfeng and Pang, Zhiqing and Wang, Qiaozi and Tan, Yiwen and Li, Qiyu and Tan, Haipeng and Chen, Jing and Yakufu, Wusiman and Wang, Zhengmin and Yang, Hongbo and Zhang, Jinyan and Sun, Dili and Weng, Xueyi and Wang, Qibing and Qian, Juying and Song, Yanan and Huang, Zheyong and Ge, Junbo},
  title = {Biomimetic Nano‐Degrader Based CD47‐SIRPα Immune Checkpoint Inhibition Promotes Macrophage Efferocytosis for Cardiac Repair},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {24},
  doi = {10.1002/advs.202306388}
}
Kostenlos starten →